Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 18,084

Document Document Title
WO/2019/194136A1
Provided are a photosensitive composition having an excellent sensitivity, a cured film, a method for manufacturing a color filter, a color filter, a solid-state imaging element, and an image display device. The photosensitive compositio...  
WO/2019/195135A1
The present invention includes substituted chromenones that are useful to inhibit the IRE1/XBP-1 pathway. In certain embodiments, the compounds of the invention inhibit IRE1s RNase activity. In other embodiments, the compounds of the inv...  
WO/2019/189555A1
Provided is a compound that can have a CDK12-inhibiting effect and that is expected to be useful as a preventive or therapeutic drug for cancer and the like. The compound or salt thereof is represented by formula (I) (where each symbol i...  
WO/2019/190239A1
The present application relates to a compound of chemical formula 1 and an organic light emitting diode comprising same.  
WO/2019/190231A1
The present specification provides a compound of chemical formula 1 and an organic light emitting diode comprising same.  
WO/2019/190241A1
The present application relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.  
WO/2019/183636A1
The present invention provides, in part, compounds of Formula I: or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the pr...  
WO/2019/181939A1
The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof, the compound or salt being useful as a novel antitumor agent targeting CSC, which is suggested to be significantly invol...  
WO/2019/182960A1
Compounds of Formula (1) as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases asso...  
WO/2019/178677A1
The present disclosure relates to the targeted delivery of defined active agents and/or immunomodulatory agents to lymph nodes or lipoid cells in a lymphatic tissue. More particularly, the invention provides methods for targeted delivery...  
WO/2019/182950A1
The present invention is directed to a compound having Formula (I) and its enantiomer: wherein the definitions of n, R, X, Y and Y3, and Z are provided in the disclosure. The invention is also directed to pharmaceutical compositions of t...  
WO/2019/182944A1
Pharmaceutical compositions of the invention comprise kinase inhibitors having a disease-modifying action in the treatment of diseases associated with BCR-ABL activity that include cancer, including chronic myeloid leukemia, acute lympho...  
WO/2019/183367A1
The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The prese...  
WO/2019/175025A1
The present invention relates to relates to novel strigolactam derivatives, to processes for preparing these derivatives including intermediate compounds, to seeds comprising these derivatives, 5 to plant growth regulator or seed germina...  
WO/2019/175160A1
The invention relates to an organic compound for optoelectronic devices. According to the invention, the organic compound has - a first chemical moiety with a structure of formula (laaa), and - two second chemical moieties, each independ...  
WO/2019/174607A1
The present invention relates to a dihydropyridophthalazinone derivative as represented by formula (I), and a preparation method therefor and an application thereof. the R1, R2, R3, m, n, ring A, and ring B in the formula are as defined ...  
WO/2019/175897A1
The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tau...  
WO/2019/170578A1
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.  
WO/2019/170063A1
The present invention provides a class of indolizine compounds represented by formula (I), pharmaceutically acceptable salts thereof, a preparation method thereof, and a use thereof. The indolizine compounds have an inhibitory effect on ...  
WO/2019/170572A1
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.  
WO/2019/172647A1
The present specification provides a compound of formula 1 and an organic light emitting device comprising same.  
WO/2019/169333A1
Described herein are compounds of Formula (I), modified polymers and implantable elements comprising compounds of Formula (II), as well as compositions and methods of use thereof. In particular, the compounds, modified polymers, implanta...  
WO/2019/169153A1
Disclosed are compounds of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6,R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure a...  
WO/2019/167982A1
The present invention pertains to: a saturated ring-condensed dihydropyrimidinone or dihydrotriazinone compound having RORγ antagonist activity or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing same;...  
WO/2019/162323A1
The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compou...  
WO/2019/161803A1
The present invention provides a peptidylarginine deiminase PAD4 inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer and tautomer thereof, and a pharmaceutical composition, a pharmaceutical p...  
WO/2019/141202A9
Disclosed is a new inhibitor compound as shown in general formula (I). The compound has a good kinase inhibitory activity. The compound of formula (I) can be used for preventing and/or treating diseases mediated by abnormal expression of...  
WO/2018/163216A9
The present invention provides a compound of general formulae I useful as GSK3β inhibitors and their anticancer potential and process for preparation of these spirooxindoles. Formula I wherein Z is hydrogen, halogen, hydroxy, alkoxy, cy...  
WO/2019/161345A1
Compounds are described with the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and n are defined as anywhere herein, which are useful for the treatment of cancer and other dysproliferative diseases.  
WO/2019/160882A1
Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.  
WO/2019/154132A1
The present invention relates to an urea-substituted aromatic ring-linked dioxazoline compound of formula (I), a pharmaceutically acceptable salt or hydrate thereof. The invention also provides a preparation method of the compound of for...  
WO/2019/154133A1
The present invention relates to a dioxazoline compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt ...  
WO/2019/150119A1
Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular...  
WO/2019/149959A1
This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy ...  
WO/2019/151697A1
Disclosed are a compound represented by chemical formula 1, an organic electric device comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode, and an electronic device ...  
WO/2019/151269A1
Provided is a compound that exhibits the effect of reducing the amount of glucosyl ceramide (e.g., the effect of accelerating glucosyl-ceramide metabolism, the effect of inhibiting glucosyl-ceramide synthesis, the effect of accelerating ...  
WO/2019/149158A1
The present invention relates to nitrogenous tricyclic compounds and uses thereof in medicine, in particular, the present invention discloses a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a ge...  
WO/2019/148043A1
Disclosed herein are compounds of Formula I'. Compounds of Formula I' inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned abo...  
WO/2019/143677A1
Compounds, methods of editing a target genomic region(s), methods of repairing of a DNA break via a HDR pathway, methods of inhibiting or suppressing repair of a DNA break via a NHEJ pathway, and methods of modifying expression of a gene...  
WO/2019/141202A1
Disclosed is a new inhibitor compound as shown in general formula (I). The compound has a good kinase inhibitory activity. The compound of formula (I) can be used for preventing and/or treating diseases mediated by abnormal expression of...  
WO/2019/143678A1
The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various d...  
WO/2019/141259A1
Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hyperuricemia and gout, a preparation method and the use the...  
WO/2019/139899A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/139907A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/139902A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/139900A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/136145A1
The invention provides methods utilizing Prins reaction in the preparation of compounds that may be useful as intermediates in the synthesis of halichondrin macrolides and analogs thereof. The invention also provides compounds that may b...  
WO/2019/132484A1
The present specification relates to a heterocyclic compound represented by formula 1 and an organic light-emitting device comprising the same.  
WO/2019/121108A1
The invention relates to an organic compound, in particular for the application in optoelectronic devices. According to the invention, the organic compound consists of - one first chemical moiety with a structure of formula I, and - one ...  
WO/2019/126731A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described ...  

Matches 1 - 50 out of 18,084